Research Article
Risk Factors for Fatal Pulmonary Hemorrhage following Concurrent Chemoradiotherapy in Stage 3B/C Squamous-Cell Lung Carcinoma Patients
Table 1
Baseline demographics and treatment characteristics.
| | Variable | All Patients
(n=505) |
| | Median age, y (range) | 65.1 (32-79) |
| | Age group, n (%) | | | ≤70 years | 423 (83.8) | | >70 years | 82 (16.2) |
| | Gender, n (%) | | | Male | 352 (69.7) | | Female | 153 (30.3) |
| | ECOG performance, n (%) | | | 0 | 205 (40.6) | | 1 | 300 (59.4) |
| | Smoking history, n (%) | | | Absent | 31 (6.1) | | Present | 474 (93.9) |
| | Median smoking duration, pack/y | 28 (0-132) |
| | Weight loss, n (%) | | | ≤5% | 395 (78.2) | | >5% | 110 (21.8) |
| | Anemia, n (%) | | | Absent | 325 (64.4) | | Present | 180 (35.6) |
| | Hemoptysis, n (%) | | | Absent | 354 (70.1) | | Present | 151(29.9) |
| | Stage, n (%) | | | 3B | 275 (54.5) | | 3C | 230 (45.5) |
| | Tumor location | | | Central | 224 (44.4) | | Peripheral | 281 (55.6) |
| | Median largest tumor size, cm (range) | 5.1 (2.4-9.8) |
| | Median tumor volume, cm3 (range) | 50.8 (19.3-149.4) |
| | Chemotherapy, n (%) | | | CV | 251 (49.8) | | CT | 226 (44.7) | | CE | 28 (5.5) |
| | Chemotherapy cycles, n (%) | | | 1 | 35 (6.9) | | 2 | 91 (18.0) | | 3 | 379 (75.1) |
| | RT technique, n (%) | | | 3D-CRT | 286 (56.7) | | IMRT | 219 (43.3) |
| | Tumor cavitation, n (%) | | | Absent | 445 (88.1) | | Present | 60 (11.9) |
|
|
Hemoglobin: <130 g/dL for men and <120 g/dL for women. ECOG: Eastern Cooperative Oncology Group; CV: Cisplatin + Vinorelbine; CT: Cisplatin + Taxane; CE: Cisplatin + Etoposide; 3D-CRT: 3-dimensional conformal radiotherapy; IMRT: intensity-modulated radiotherapy. |
